King Pharmaceuticals

King, Donaldson Lead High-Flying Stocks

The Street (Free subscription) | 20/11/2009

Canadian Solar, King Pharmaceuticals, Teck Resources and Merck hit 52-week highs.

Notable 52-Week NYSE New Highs and Lows 11/19: CAH, DCI, RX, KG, MRK, TSL Highs; SNV, WNR Low

StreetInsider.com News Articles (Free subscription) | 19/11/2009

Notable 52-week Highs on the NYSE: Cardinal Health, Inc. (NYSE: CAH) - Hit $31.77. UBS initiated coverage with a Buy rating on Cardinal. Donaldson Company Inc. (NYSE: DCI) - touched $45.09. The company reported Q110 earnings about the Street estimates today. IMS Health Inc. (NYSE: RX) - reached $21.65 King Pharmaceuticals Inc. (NYSE: KG) - hit $11.88. May be benefitting from mixed ZymoGenetics ratings...

Earn Cash From King Pharmaceuticals (KG)'s New High

MarketIntelligenceCenter.com (Free subscription) | 19/11/2009

King Pharmaceuticals (NYSE: KG) hit a new 52-Week high of $11.91 so far today. Currently the stock is up $0.67 (5.98%) to $11.87 on 4,102,031 shares traded. Today's high is up $6.01 from a 52-Week Low of $5.86. King Pharmaceuticals stock has been showing support around $10.98 and resistance in the $11.44 range. Technical indicators for the stock are neutral and ...

Wall St Sense: Complimentary Research Report on ATI, GGB, KG, A, HCP and DNE by WallStSense.com

Market Wire (Free subscription) | 19/11/2009

NEW DELHI, INDIA (MARKET WIRE) Wallstsense.com is an online community with a dedicated team of analysts who are providing free in-depth research on North American equities. Our analysts have issued complimentary analysis on the following six companies: Allegheny Technologies Inc. (NYSE: ATI), Gerdau S.A. (NYSE: GGB), King Pharmaceuticals Inc. (NYSE: KG), Agilent Technologies Inc. (NYSE: A), HCP Inc....

King Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference

Business Wire (Free subscription) | 13/11/2009

BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009, at 2:15 pm EST, at the St. Regis Hotel in New York, New York. The presentation may include a discussion of the Company’s marketed products, pipeline, strategy for growth, financial results and expectations,...

ZymoGenetics, King Pharma Brawl Over Drugs to Control Surgical Bleeding

Xconomy (Free subscription) | 09/11/2009

ZymoGenetics started really playing hardball with King Pharmaceuticals in August, and now a high-and-tight fastball has come right back at the Seattle biotech company. The projectile in question is a lawsuit filed on November 2 by Bristol, TN-based King in the U.S. District Court in Eastern Tennessee; the suit accuses ZymoGenetics of false advertising, unfair competition, [...]

Analyst Choice: AnalystChoice.com Brings You the Best Complimentary Research Report on A, DVN, KG, IAG, MMC and AEM

Market Wire (Free subscription) | 09/11/2009

NEW DELHI, INDIA (MARKET WIRE) Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. Today we have begun in-depth reporting on our website evaluating the current market condition of Agilent Technologies Inc. (NYSE: A), Devon Energy Corporation (NYSE: DVN), King Pharmaceuticals Inc. (NYSE: KG), IAMGOLD...

King Pharma Income Statement Analysis for September 2009 Quarter

SeekingAlpha.com (Free subscription) | 09/11/2009

Neil Carvin submits: King Pharmaceuticals, Inc. (NYSE: KG ) earned $0.17 per share in the third quarter of 2009, down from $0.34 in the same quarter of last year. On a non - GAAP (" pro forma " or "ex-items") basis, earnings fell from $0.39 to $0.29 per share. The pretax difference between GAAP and non-GAAP Net Income was $46 million in the latest quarter. The most substantial...

KG: Income Statement Analysis for the September 2009 Quarter

Gauging Corporate Financial Results (Free subscription) | 09/11/2009

King Pharmaceuticals, Inc. ( NYSE: KG ) earned $0.17 per share in the third quarter of 2009, down from $0.34 in the same quarter of last year. On a non - GAAP (" pro forma " or "ex-items") basis, earnings fell from $0.39 to $0.29 per share. The pretax difference between GAAP and non-GAAP Net Income was $46 million in the latest quarter. The most substantial item excluded from the...

King Beats, But Earnings Down

iStockAnalyst.com (Free subscription) | 05/11/2009

King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses. [More...]

King 3Q profit falls on charges, but tops forecast

Daily Advance - Business (Free subscription) | 05/11/2009

BRISTOL, Tenn. — Drug developer King Pharmaceuticals said Thursday its third-quarter profit wa...

King Pharmaceuticals (KG) NewsBite - KG Up Nearly 4% After Better Than Expected Earnings

MarketIntelligenceCenter.com (Free subscription) | 05/11/2009

King Pharmaceuticals (NYSE: KG) opened at $10.30. So far today, the stock has hit a low of $10.30 and a high of $10.70. KG is now trading at $10.59, up $0.40 (3.93%). The stock hit its 52-Week high of $11.36 in earlier this month and set its 52-Week low of $5.86 in March. The stock is moving higher today after this morning's earnings report. Th...

King 3Q profit falls on charges, but tops forecast

Seattle Times (Free subscription) | 05/11/2009

Drug developer King Pharmaceuticals said Thursday its third-quarter profit was cut in half by charges for related to its $1.6 billion buyout of rival Alpharma Inc.

King 3Q profit falls on charges, but tops forecast

San Fransisco Chronicle (Free subscription) | 05/11/2009

Drug developer King Pharmaceuticals said Thursday its third-quarter profit was cut in half by charges for related to its $1.6 billion buyout of rival Alpharma Inc. Still, the company topped Wall Street forecasts, with revenue gaining ground from the addition... Wall Street - King Pharmaceuticals - Business - United States - Biotechnology and Pharmaceuticals

• King 3Q profit falls on charges, but tops forecast - Miami Herald

King Pharmaceuticals reports profit fall

Market Watch (Free subscription) | 05/11/2009

NEW YORK (MarketWatch) -- King Pharmaceuticals Inc. said Thursday its third-quarter profit fell to $42 million, or 17 cents a share, from $82 million, or 34 cents a share, in the year-ago period. Total revenues rose 19.3% to $463 million. The Bristol, Tenn.-based pharmaceutical company said adjusted earnings were 29 cents a share. Analysts surveyed by FactSet Research had expected, on average, earnings...